I wrote this just ahead of $ARGX announcing the $2.2bn acquisition of Forte this a.m. as more SMID cap companies get commercial momentum and plot long-term growth plans. SMID Caps In The Buyer’s Seat insights.citeline.com/scrip/…

Drug makers may have dodged the worst of the drug pricing outcomes, but if there is no difference in the cost of drugs for US patients in the end, then industry hasn’t really solved the problem. It will resurface again and again. insights.citeline.com//scrip…

"Medicaid is immaterial for $PFE, because Medicaid represents less than 5% of US sales and an even smaller percentage of global sales," Leerink analysts say after $PFE announces drug pricing deal with Trump to lower Medicaid prices.

The exemption is a relief to industry, which is trying to stay focused on business as usual despite chaotic disruptions at US health agencies. But the situation remains fluid and some caution the policy could change. insights.citeline.com//scrip…

Pharmaceuticals exempt from Trump tariffs, according to WH fact sheet.

Dealmakers said #JPM25 was quieter than prior years, and outside of the initial deals announced, news was scarce and corporate updates underwhelmed. Weather sure was nice though. insights.citeline.com//scrip…

Also from @FT pharma summit pink.citeline.com/articles/2…

FTC Deputy director of the Bureau of Competition Rahul Rao talked about the agency's views on pharma consolidation and actions some in the industry have viewed as controversial @ the FT pharma summit. scrip.citeline.com/articles/…

Rosier macro-economic outlook and excitement over new breakthroughs was juxtaposed against the challenge of paying for them and the dawning realization that the US health care system is pushing back against the industry in very real and tangible ways.scrip.citeline.com/articles/…

Visited $PFE’s new NYC headquarters in Hudson Yards this am. What’s on the bookshelves (along with a fave @emmastraub Modern Lovers) Thanks Pfizer for having me.

Regeneron CEO Takes Industry Counterview On FTC News: “I’m Glad They’re Looking Into This” :: Scrip scrip.pharmaintelligence.inf…

“I’m glad that the FTC is looking at this,” $ REGN CEO Len Schleifer says at #ftpharma summit. He points out Regeneron has pending litigation with $AMGN over rebate practices related to PCSK9s.

FTC is blocking $AMGN acquisition of $HZNP …over a history of bundling rebates, long a common practice among big pharma manufacturers. This, despite Amgen agreeing not to bundle the Horizon products.

$BMY has changed dramatically since Caforio took the helm in 2015, transitioning away from antivirals while growing into an oncology/CV leader with $46.2bn in 2022 revenues, versus $16.5bn in 2015, driven by the growth of Eliquis/Opdivo, and Celgene. scrip.pharmaintelligence.inf…

$AMGN wins appeals court decision on #Otezla, protecting the oral psoriasis drug from generic competition until 2028. It was approved in 2014.

PhRMA's incoming board chair and $NVS CEO Vasant Narasimhan talks to @PharmaPinkSheet about efforts to improve Medicare drug price negotiation policies stemming from IRA. pink.pharmaintelligence.info…

$VRTX's R&D strategy is centered on being therapeutically agnostic; the firm will soon have to put that strategy to the commercial test. COO Stuart Arbuckle & CSO David Altshuler talked to Scrip. scrip.pharmaintelligence.inf…

Aiming to solve some big commercial challenges in the US, $NVS has put in place a new vertical commercial structure, reduced its therapeutic area focus to emphasize broader market issues instead, and recruited marketing experts from outside industry. scrip.pharmaintelligence.inf…

It was great to be back at #JPM23; I didn't miss the bottlenecks in the Westin but did miss the spontaneity that sometimes came out of the breakout rooms. The atmosphere felt a bit tense, but the North star remains innovation. scrip.pharmaintelligence.inf…

The way my #JPM23 is going in a photo.